Shelter Pharma Converts Warrants Into Equity Shares, Raises Rs. 36,12,375

Shelter Pharma Limited has successfully converted warrants into equity shares, marking a significant milestone in its capital structure enhancement. The pharmaceutical company's board of directors approved the conversion of 2,79,000 warrants into 1,14,000 equity shares during their meeting held on May 01, 2026.

Warrant Conversion Details

The conversion process involved three non-promoter investors who exercised their option to convert warrants into equity shares. The board approved the allotment of 1,14,000 equity shares of face value Rs. 10 each, fully paid, upon receipt of the remaining exercise price.

Parameter Details Warrants Converted 2,79,000 Equity Shares Allotted 1,14,000 Face Value per Share Rs. 10 Exercise Price per Warrant Rs. 31.6875 Total Amount Raised Rs. 36,12,375

Investor Participation

Three non-promoter investors participated in the warrant conversion process, with varying levels of conversion from their allocated warrants.

Investor Name Warrants Allotted Warrants Already Converted Shares Converted Amount Paid (Rs.) Outstanding Warrants Dipika Pankajbhai Patel 99,000 78,000 21,000 665,437.50 0 Rucha Kamleshbhai Trivedi 102,000 0 51,000 1,616,062.50 51,000 Sahil Tanojkumar Shah 51,000 0 42,000 1,330,875.00 9,000 Total 252,000 78,000 114,000 36,12,375.00 60,000

Capital Structure Impact

The warrant conversion has resulted in an expansion of the company's equity base. The paid-up equity share capital increased from Rs. 166117920 consisting of 16611792 equity shares to Rs. 167257920 consisting of 16725792 equity shares, all with face value of Rs. 10 each.

The newly allotted equity shares rank pari-passu with existing equity shares of the company in all respects. The allotment was made for cash upon receipt of the remaining exercise price of Rs. 31.6875 per warrant, representing 75% of the original warrant issue price of Rs. 42.25 per warrant.

Background and Regulatory Compliance

The warrant conversion follows the company's earlier disclosure dated August 06, 2025, regarding the allotment of 88,08,000 convertible equity warrants. The original warrant allotment was approved by shareholders at the Extra Ordinary General Meeting held on July 23, 2025, and received in-principle approval from BSE Limited through their letter dated July 22, 2025.

The warrants were issued at Rs. 42.25 each, including a premium of Rs. 32.25 per warrant, with initial subscription money collected at 25% of the issue price. The company will apply for listing and trading approval from the stock exchange for the newly issued equity shares in due course.

Meeting Details

The board meeting commenced at 12:00 P.M. and concluded at 12:15 P.M. on May 01, 2026. The decision was made in compliance with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Shelter Pharma Limited has announced the commencement of product dispatch operations to Sudan, marking another milestone in its international expansion strategy. The pharmaceutical company disclosed this development under SEBI Regulation 30 on April 16, 2026.

Export Operations to Sudan

The company has begun loading stocks for shipment to Sudan, which includes its flagship product "Allvitamin", a daily multivitamin supplement. This dispatch forms part of Shelter Pharma Limited's regular export supply operations to African markets, demonstrating the company's established presence in the region.

Parameter: Details Event Date: April 15, 2026 Destination Market: Sudan Key Product: Allvitamin (daily multivitamin supplement) Market Focus: African markets Nature of Operations: Regular export supply

Strategic Market Positioning

This export initiative reflects Shelter Pharma Limited's continued commitment to strengthening its global presence and maintaining consistent supply relationships in international markets. The company's focus on African markets demonstrates its strategic approach to geographic diversification and market expansion.

Business Impact

The export operations contribute to the company's revenue diversification strategy and support business growth through international market penetration. The regular supply arrangements with African markets indicate established trade relationships and operational consistency in the company's export business.

Regulatory Compliance

The announcement was made pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, ensuring transparency in the company's operational developments for stakeholders and investors.

We’re building Scanx - to help you express your trading & investing idea, to help you analyse the markets better.

Stock Markets are the true indicator of the growth of any country's economy. We are bullish on India, we are bullish on India's prospects to be one of largest economies of the world. We believe that Stock Markets provide an unique opportunity for all Indians to participate in the growth story of India. We are enabling the same for Indians.

As financial services are becoming more accessible, there is now a large set of Indians today who are financially aware and literate. They value time and seek high quality products & services. Most screening, trading, investing platforms available today are more or less similar to each other, and they have not evolved with time. While both traders & investors have gotten smart about how they make money and build wealth, as users they have continued to use the same products, features, and platforms that were available for years with little or no innovation. We plan to change that - a technology-led platform built for super traders and long term investors.